site:www.urotoday.com - Search Videos

5002-xaluritamig-vs-standard-care-a-phase-3-trial-for-arpi-taxane ...

5002-xaluritamig-vs-standard-care-a-phase-3-trial-for-arpi-taxane ...

Monitoring the Marrow: Hematologic Toxicity in the Treatment of Advanced Prostate Cancer "Presentation" - Daniel Childs

Monitoring the Marrow: Hematologic Toxicity in the Treatment of Advanced Prostate Cancer "Presentation" - Daniel Childs

Patient Selection and Outcomes for Partial Cystectomy in Muscle-Invasive Bladder Cancer - Wei Shen Tan

Patient Selection and Outcomes for Partial Cystectomy in Muscle-Invasive Bladder Cancer - Wei Shen Tan

Phase 1B Trial Combines Xaluritamig with Hormone Therapy for Metastatic Prostate Cancer - Nicholas Zorko

Phase 1B Trial Combines Xaluritamig with Hormone Therapy for Metastatic Prostate Cancer - Nicholas Zorko

IBCG Recommendations for Intermediate-Risk NMIBC Definitions and Management - Roger Li

IBCG Recommendations for Intermediate-Risk NMIBC Definitions and Management - Roger Li

TRIPLE-SWITCH Trial Tests Docetaxel Addition for mHSPC Patients with Suboptimal PSA Response - Alexandra Sokolova

TRIPLE-SWITCH Trial Tests Docetaxel Addition for mHSPC Patients with Suboptimal PSA Response - Alexandra Sokolova

Balancing Treatment Intensification and Quality of Life in Elderly Prostate Cancer Patients - Rana McKay

Balancing Treatment Intensification and Quality of Life in Elderly Prostate Cancer Patients - Rana McKay

PARP Inhibitors in Prostate Cancer: A Decade of Development and the Combination vs Monotherapy Debate for HRR-Mutated Disease - Neeraj Agarwal

Final Analysis of Phase 3 POTOMAC Study in High-Risk NMIBC - Maria De Santis

Gut Microbiome and Prostate Cancer: How Diet Impacts Disease Progression - Robert Thomas

ARTISAN Trial: Evaluating Lead-212 PSMA Therapy for Advanced Prostate Cancer - Oliver Sartor

EMBARK Analysis: Testosterone Recovery Post-ADT in High-Risk Prostate Cancer Patients - Stephen Freedland

Examining Survival Rates in Prostate Cancer: Exploring the STAMPEDE Platform, Journal Club - Rashid Sayyid & Zachary Klaassen

Beyond Lutetium PSMA: Exploring Terbium-161 for Treatment-Resistant Prostate Cancer "Presentation" - Michael Hofman

Phase III PSMAfore Trial: Final Survival and Safety Data in mCRPC, Journal Club - Rashid Sayyid & Zachary Klaassen

Symmetry, Visibility, and Control: The Advantages of the BioProtect Balloon in Prostate Cancer Treatment - Edward Soffen

HoLEP vs ThuLEP: Comparing Laser Enucleation Techniques in Prostate Surgery "Presentation" - Bruce Gao

Complete vs Partial TURBT for Muscle-Invasive Bladder Cancer Treatment - Fredrik Liedberg, Marco Moschini & Benjamin Pradere

Reading and Reporting a PSMA PET Scan for Staging Prostate Cancer - Andrea Farolfi

PROMISE Criteria: Enhanced Survival Prediction in Prostate Cancer with PSMA PET - Wolfgang Fendler

Targeting NSD2 to Reverse Treatment Resistance in Advanced Prostate Cancer - Jia Li

EZH2 Inhibition in Prostate Cancer: MEVPRO-1 Phase III Trial Update - Neeraj Agarwal

Targeting EZH2 in Prostate Cancer: The Role of Mevrometostat in Preventing Neuroendocrine Differentiation - Michael Schweizer

Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann

Final Results of the SunRISe-4 Study in Muscle-Invasive Bladder Cancer - Andrea Necchi

Targeting SPP1+ Macrophages and the Adenosine Pathway to Boost Prostate Cancer Immunotherapy - Lawrence Fong

Integrating Advanced Practice Providers into Urological Practice Settings - Taylor Brewer, Tara Cumming & Meredith Donahue

Analysis of MRI Use in the Diagnostic Pathway for Bladder Cancer - Nicholas James

Treatment Options for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer - Kelly Stratton

Phase III CAPItello-281 Trial Results for mHSPC with PTEN Loss - Karim Fizazi

See more